Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ocular Therapeutix (OCUL) Non Operating Income (2016 - 2025)

Ocular Therapeutix (OCUL) has 13 years of Non Operating Income data on record, last reported at $5.1 million in Q4 2025.

  • For Q4 2025, Non Operating Income rose 133.36% year-over-year to $5.1 million; the TTM value through Dec 2025 reached $4.1 million, up 118.77%, while the annual FY2025 figure was $4.1 million, 118.77% up from the prior year.
  • Non Operating Income reached $5.1 million in Q4 2025 per OCUL's latest filing, up from -$720000.0 in the prior quarter.
  • Across five years, Non Operating Income topped out at $23.3 million in Q1 2021 and bottomed at -$33.2 million in Q1 2024.
  • Average Non Operating Income over 5 years is $3.2 million, with a median of $1.7 million recorded in 2022.
  • Peak YoY movement for Non Operating Income: surged 975.99% in 2021, then plummeted 340.14% in 2023.
  • A 5-year view of Non Operating Income shows it stood at $14.2 million in 2021, then plummeted by 73.1% to $3.8 million in 2022, then crashed by 340.14% to -$9.2 million in 2023, then skyrocketed by 123.86% to $2.2 million in 2024, then skyrocketed by 133.36% to $5.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non Operating Income were $5.1 million in Q4 2025, -$720000.0 in Q3 2025, and -$172000.0 in Q2 2025.